Soft chewy confection comprising hmo
US-2024000098-A1 · Jan 4, 2024 · US
US9539269B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9539269-B2 |
| Application number | US-201113334933-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 22, 2011 |
| Priority date | Dec 31, 2010 |
| Publication date | Jan 10, 2017 |
| Grant date | Jan 10, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Disclosed are methods of reducing the incidence of necrotizing enterocolitis in an infant, toddler, or child using nutritional compositions including human milk oligosaccharides. The nutritional compositions including the human milk oligosaccharides are effective in reducing inflammation and the incidence of inflammatory diseases.
Opening claim text (preview).
What is claimed is: 1. A method of reducing the incidence of necrotizing enterocolitis in an infant, toddler, or child, the method comprising administering to an infant, toddler, or child in need thereof, a nutritional composition comprising human milk oligosaccharides selected from the group consisting of 2′-fucosyllactose, lacto-N-neotetraose, and combinations thereof in a total amount of from about 0.001 mg/mL to about 20 mg/mL. 2. The method of claim 1 , wherein the composition comprises from 0.001 mg/mL to less than 2 mg/mL 2′-fucosyllactose. 3. The method of claim 1 , wherein the composition comprises from 0.001 mg/mL to less than 0.2 mg/mL lacto-N-neotetraose. 4. The method of claim 1 , wherein the composition further comprises at least one of a prebiotic, a probiotic, a long chain polyunsaturated fatty acid, an antioxidant, a milk protein of human origin, a milk protein of bovine origin, and a milk protein of combined bovine and human origin. 5. A method of reducing the incidence of necrotizing enterocolitis in an infant, toddler, or child, the method comprising administering to an infant, toddler, or child in need thereof a nutritional composition comprising 6′-sialyllactose, 2′-fucosyllactose, and lacto-N-neotetraose wherein the 6′-sialyllactose, 2′-fucosyllactose, and lacto-N-neotetraose are present in a total amount of from about 0.001 mg/mL to about 20 mg/mL. 6. The method of claim 5 , wherein the nutritional composition comprises from 0.001 mg/mL to less than 0.25 mg/mL 6′-sialyllactose. 7. The method of claim 5 , wherein the nutritional composition comprises from 0.001 mg/mL to less than 2 mg/mL 2′-fucosyllactose. 8. The method of claim 5 , wherein the nutritional composition comprises from 0.001 mg/mL to less than 0.2 mg/mL lacto-N-neotetraose. 9. The method of claim 5 , wherein the synthetic nutritional composition further comprises at least one of a prebiotic, a probiotic, a long chain polyunsaturated fatty acid, an antioxidant, and a milk protein of human origin, a milk protein of bovine origin, and a milk protein of combined bovine and human origin. 10. A synthetic formula for improving the feeding tolerance of an infant, toddler, or child, the synthetic formula comprising from about 0.001 mg/mL to about 20 mg/mL of an oligosaccharide blend and an emulsifying agent, wherein the oligosaccharide blend comprises a first oligosaccharide selected from the group consisting of a fructooligosaccharide, a galactooligosaccharide, lacto-N-neotetraose, 2′-fucosyllactose, and combinations thereof; a second oligosaccharide selected from the group consisting of 3′-sialyllactose, 6′-sialyllactose, and combinations thereof; and a third oligosaccharide selected from the group consisting of inulin, a gum, polydextrose, and combinations thereof. 11. The synthetic formula of claim 10 , wherein the oligosaccharide blend comprises from about 0.001 mg/mL to about 20 mg/mL of the first oligosaccharide, from about 0.001 mg/mL to about 20 mg/mL of the second oligosaccharide, and from about 0.05 mg/mL to about 20 mg/mL of the third oligosaccharide. 12. The synthetic formula of claim 10 , wherein the first oligosaccharide comprises lacto-N-neotetraose in a concentration of from 0.01 mg/mL to less than 0.2 mg/mL. 13. The synthetic formula of claim 10 , wherein the first oligosaccharide comprises lacto-N-neotetraose in a concentration of from greater than 0.32 mg/mL to 10 mg/mL. 14. The synthetic formula of claim 10 , wherein the first oligosaccharide comprises 2′-fucosyllactose in a concentration of from 0.001 mg/mL to less than 2.0 mg/mL. 15. The synthetic formula of claim 10 , wherein the first oligosaccharide comprises 2′-fucosyllactose in a concentration of from greater than 2.5 mg/mL to 10 mg/mL. 16. The synthetic formula of claim 10 , wherein the second oligosaccharide comprises 6′-sialyllactose in a concentration of from 0.001 mg/mL to less than 0.25 mg/mL. 17. The synthetic formula of claim 10 , wherein the second oligosaccharide comprises 6′-sialyllactose in a concentration of from greater than 0.4 mg/mL to 10 mg/mL. 18. A method of improving the feeding tolerance of an infant, toddler, or child in need thereof, the method comprising administering to the infant, toddler, or child a nutritional composition comprising from about 0.001 mg/mL to about 20 mg/mL of an oligosaccharide blend, wherein the oligosaccharide blend comprises a first oligosaccharide selected from the group consisting of a fructooligosaccharide, a galactooligosaccharide, lacto-N-neotetraose, 2′-fucosyllactose, and combinations thereof; a second oligosaccharide selected from the group consisting of 3′-sialyllactose, 6′-sialyllactose, and combinations thereof; and a third oligosaccharide selected from the group consisting of inulin, a gum, polydextrose, and combinations thereof.
Free radical scavengers or antioxidants · CPC title
Nutrients, e.g. vitamins, minerals · CPC title
Drugs for disorders of the alimentary tract or the digestive system · CPC title
Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula · CPC title
from milk · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.